FDA issues warning on 4 widely-used asthma drugs

Feb 18, 2010 By LAURAN NEERGAARD , AP Medical Writer

(AP) -- The government is issuing new restrictions on some widely used long-acting asthma drugs, saying they should never be used without other asthma controllers to prevent a lifethreatening risk.

Four medications - Foradil, Serevent, Advair and Symbicort - contain an ingredient that relaxes muscles in the lung's airways. While they're very helpful for some patients, the way they work also may mask symptoms that can trigger serious attacks. It's a particular concern for children.

The ordered new labels saying the drugs should be used for the shortest possible duration - and only together with other medications such as inhaled steroids that work differently, by relieving airway inflammation.

Explore further: FDA OKs Cubist antibiotic for serious infections

5 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

Asthma risk increases in children treated for HIV

Jul 01, 2008

Children whose immune systems rebound after treatment with potent anti-viral drugs for HIV infection face an increased risk of developing asthma, said a federally funded consortium of researchers led by those from Baylor ...

More pounds equals worse asthma?

May 22, 2007

A new study presented at the American Thoracic Society 2007 International Conference finds that obese people are significantly more likely to have persistent or severe persistent asthma than their thinner counterparts.

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

11 hours ago

The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient access ...

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.